Education
About Us
Working with TipRanks
Follow Us
SanBio Co (JP:4592)
OTHER OTC:4592
4592 Stock Chart & Stats
¥2230.00
¥19.00(2.53%)
At close: 4:00 PM EST
¥2230.00
¥19.00(2.53%)
Day’s Range― - ―
52-Week Range¥661.00 - ¥3,990.00
Previous CloseN/A
Volume765.40K
Average Volume (3M)2.08M
Market Cap
¥132.41B
Enterprise Value¥165.36B
Total Cash (Recent Filing)¥2.74B
Total Debt (Recent Filing)¥1.36B
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Mar 23, 2026EPS Estimate
-20.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.95
Shares Outstanding78,028,330
10 Day Avg. Volume2,869,570
30 Day Avg. Volume2,080,090
Financial Highlights & Ratios
PEG Ratio-5.05
Price to Book (P/B)28.13
Price to Sales (P/S)0.00
P/FCF Ratio-13.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SanBio Co News
4592 FAQ
What was SanBio Co’s price range in the past 12 months?
SanBio Co lowest stock price was ¥661.00 and its highest was ¥3990.00 in the past 12 months.
What is SanBio Co’s market cap?
SanBio Co’s market cap is ¥132.41B.
When is SanBio Co’s upcoming earnings report date?
SanBio Co’s upcoming earnings report date is Mar 23, 2026 which is in 71 days.
How were SanBio Co’s earnings last quarter?
SanBio Co released its earnings results on Dec 15, 2025. The company reported -¥9.95 earnings per share for the quarter, beating the consensus estimate of -¥15.351 by ¥5.401.
Is SanBio Co overvalued?
According to Wall Street analysts SanBio Co’s price is currently Overvalued.
Does SanBio Co pay dividends?
SanBio Co does not currently pay dividends.
What is SanBio Co’s EPS estimate?
SanBio Co’s EPS estimate is -20.69.
How many shares outstanding does SanBio Co have?
SanBio Co has 78,028,330 shares outstanding.
What happened to SanBio Co’s price movement after its last earnings report?
SanBio Co reported an EPS of -¥9.95 in its last earnings report, beating expectations of -¥15.351. Following the earnings report the stock price went up 1.093%.
Which hedge fund is a major shareholder of SanBio Co?
Currently, no hedge funds are holding shares in JP:4592
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SanBio Co
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
4592 Company Deck
4592 Earnings Call
Q2 2025
0:00 / 0:00
Technical Analysis
Options Prices
Currently, No data available
---